DANSEY ROGER D 4

What Happened

• Roger D. Dansey, a director of Nurix Therapeutics (NRIX), received an award of derivative securities on 2026-05-15 covering 31,250 shares. The filing reports an acquisition (code A) at $0.00 (derivative), indicating an equity award (stock option) rather than an open‑market purchase or sale.

Key Details

• Transaction date and filing date: 2026-05-15 (filed timely).
• Transaction type: Award/Grant of derivative securities (Form 4 code A).
• Quantity: 31,250 underlying shares; price reported as $0.00 (derivative award).
• Shares owned after the transaction: not provided in the information supplied.
• Footnote: The award is a stock option that vests 100% on the earlier of (a) the date of the next annual meeting of stockholders or (b) May 15, 2027, in each case contingent on the reporting person’s continued service.
• Timeliness: Filing appears timely (transaction date = report date); no late filing flag noted.

Context

• This filing reflects a compensation-related option award that vests in the future; it is not an immediate purchase or sale of shares and does not indicate an exercised-and-sold (cashless) transaction. Such awards are commonly used for director compensation and to align incentives with shareholders; they do not by themselves signal a buy or sell view by the insider.